Epidural hematoma after total knee arthroplasty in a patient receiving rivaroxaban: A case report
Anesthesia and Pain Medicine
;
: 102-105, 2019.
Article
Dans Anglais
| WPRIM
| ID: wpr-719395
ABSTRACT
Rivaroxaban, a factor Xa inhibitor, is one of the newly developed direct oral anticoagulants (DOAC). In recent times, it has been increasingly used in the prevention of pulmonary embolism in patients undergoing orthopedic surgery. This report describes a case of epidural hematoma in an elderly patient who underwent combined spinal epidural anesthesia for total knee arthroplasty; the patient received rivaroxaban postoperatively for 7 days to prevent pulmonary embolism. Additionally, the epidural hematomas developed on the 5th postoperative day but the patient recovered well with conservative treatment. Although rivaroxaban has a low need for monitoring and is easily administered, the guidelines should be carefully checked for the postoperative administration schedule in patients undergoing regional anesthesia. In addition, rivaroxaban should be used with caution, especially in elderly patients.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Orthopédie
/
Rendez-vous et plannings
/
Embolie pulmonaire
/
Facteur Xa
/
Arthroplastie prothétique de genou
/
Hématome épidural rachidien
/
Rivaroxaban
/
Hématome
/
Anesthésie de conduction
/
Anesthésie péridurale
Type d'étude:
Guide de pratique
Limites du sujet:
Adulte très âgé
/
Humains
langue:
Anglais
Texte intégral:
Anesthesia and Pain Medicine
Année:
2019
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS